Edward Dulac III Sells 4,677 Shares of Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Edward Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. This trade represents a 2.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Intellia Therapeutics Stock Performance

NASDAQ NTLA traded up $0.28 during trading hours on Monday, reaching $17.84. The company’s stock had a trading volume of 3,834,214 shares, compared to its average volume of 5,666,633. The stock has a market cap of $2.49 billion, a PE ratio of -5.04 and a beta of 1.77. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The company’s 50-day moving average is $14.13 and its two-hundred day moving average is $13.07.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. The company had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the previous year, the business posted ($1.10) earnings per share. Equities analysts expect that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Citizens Jmp reiterated a “market outperform” rating and set a $30.00 target price on shares of Intellia Therapeutics in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. Robert W. Baird lifted their price objective on Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday, April 27th. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research note on Monday, June 15th. Finally, Truist Financial upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Hold” and an average target price of $20.46.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP acquired a new position in Intellia Therapeutics during the first quarter valued at approximately $404,000. Avidity Partners Management LP acquired a new stake in shares of Intellia Therapeutics in the first quarter worth $962,000. Wellington Grp LLC increased its position in shares of Intellia Therapeutics by 50.9% in the first quarter. Wellington Grp LLC now owns 46,297 shares of the company’s stock worth $594,000 after acquiring an additional 15,620 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock valued at $17,713,000 after acquiring an additional 139,325 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Intellia Therapeutics in the 1st quarter valued at $250,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.